641 related articles for article (PubMed ID: 29807101)
61. AMPK: a target for drugs and natural products with effects on both diabetes and cancer.
Hardie DG
Diabetes; 2013 Jul; 62(7):2164-72. PubMed ID: 23801715
[TBL] [Abstract][Full Text] [Related]
62. Is Metformin a Therapeutic Paradigm for Colorectal Cancer: Insight into the Molecular Pathway?
Thent ZC; Zaidun NH; Azmi MF; Senin MI; Haslan H; Salehuddin R
Curr Drug Targets; 2017; 18(6):734-750. PubMed ID: 27919208
[TBL] [Abstract][Full Text] [Related]
63. Metformin: Is it a drug for all reasons and diseases?
Triggle CR; Mohammed I; Bshesh K; Marei I; Ye K; Ding H; MacDonald R; Hollenberg MD; Hill MA
Metabolism; 2022 Aug; 133():155223. PubMed ID: 35640743
[TBL] [Abstract][Full Text] [Related]
64. Metformin action on AMP-activated protein kinase: a translational research approach to understanding a potential new therapeutic target.
Boyle JG; Salt IP; McKay GA
Diabet Med; 2010 Oct; 27(10):1097-106. PubMed ID: 20854376
[TBL] [Abstract][Full Text] [Related]
65. Perspectives of metformin use in endometrial cancer and other gynaecological malignancies.
Barczyński B; Frąszczak K; Kotarski J
J Drug Target; 2022 Apr; 30(4):359-367. PubMed ID: 34753372
[TBL] [Abstract][Full Text] [Related]
66. Metformin and insulin meet in a most atypical way.
White MF
Cell Metab; 2009 Jun; 9(6):485-7. PubMed ID: 19490902
[TBL] [Abstract][Full Text] [Related]
67. Metformin, an old drug, brings a new era to cancer therapy.
He H; Ke R; Lin H; Ying Y; Liu D; Luo Z
Cancer J; 2015; 21(2):70-4. PubMed ID: 25815846
[TBL] [Abstract][Full Text] [Related]
68. Diabetes mellitus and increased risk of cancer: focus on metformin and the insulin analogs.
McFarland MS; Cripps R
Pharmacotherapy; 2010 Nov; 30(11):1159-78. PubMed ID: 20973689
[TBL] [Abstract][Full Text] [Related]
69. Metformin primarily decreases plasma glucose not by gluconeogenesis suppression but by activating glucose utilization in a non-obese type 2 diabetes Goto-Kakizaki rats.
Yoshida T; Okuno A; Tanaka J; Takahashi K; Nakashima R; Kanda S; Ogawa J; Hagisawa Y; Fujiwara T
Eur J Pharmacol; 2009 Nov; 623(1-3):141-7. PubMed ID: 19765581
[TBL] [Abstract][Full Text] [Related]
70. The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling.
Scherbakov AM; Sorokin DV; Tatarskiy VV; Prokhorov NS; Semina SE; Berstein LM; Krasil'nikov MA
IUBMB Life; 2016 Apr; 68(4):281-92. PubMed ID: 26892736
[TBL] [Abstract][Full Text] [Related]
71. Metformin and cancer: licence to heal?
Papanas N; Maltezos E; Mikhailidis DP
Expert Opin Investig Drugs; 2010 Aug; 19(8):913-7. PubMed ID: 20557275
[TBL] [Abstract][Full Text] [Related]
72. Regulation of glucose-6-phosphatase gene expression by insulin and metformin.
Mues C; Zhou J; Manolopoulos KN; Korsten P; Schmoll D; Klotz LO; Bornstein SR; Klein HH; Barthel A
Horm Metab Res; 2009 Oct; 41(10):730-5. PubMed ID: 19579180
[TBL] [Abstract][Full Text] [Related]
73. Bright renoprotective properties of metformin: beyond blood glucose regulatory effects.
Nasri H; Baradaran A; Ardalan MR; Mardani S; Momeni A; Rafieian-Kopaei M
Iran J Kidney Dis; 2013 Nov; 7(6):423-8. PubMed ID: 24241085
[TBL] [Abstract][Full Text] [Related]
74. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
75. Metabolic switching in the hypoglycemic and antitumor effects of metformin on high glucose induced HepG2 cells.
Lv Y; Tian N; Wang J; Yang M; Kong L
J Pharm Biomed Anal; 2018 Jul; 156():153-162. PubMed ID: 29705631
[TBL] [Abstract][Full Text] [Related]
76. Metformin as first choice in oral diabetes treatment: the UKPDS experience.
Holman R
Journ Annu Diabetol Hotel Dieu; 2007; ():13-20. PubMed ID: 18613325
[TBL] [Abstract][Full Text] [Related]
77. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
Lin CC; Yeh HH; Huang WL; Yan JJ; Lai WW; Su WP; Chen HH; Su WC
Am J Respir Cell Mol Biol; 2013 Aug; 49(2):241-50. PubMed ID: 23526220
[TBL] [Abstract][Full Text] [Related]
78. Metformin attenuates motility, contraction, and fibrogenic response of hepatic stellate cells
Li Z; Ding Q; Ling LP; Wu Y; Meng DX; Li X; Zhang CQ
World J Gastroenterol; 2018 Feb; 24(7):819-832. PubMed ID: 29467552
[TBL] [Abstract][Full Text] [Related]
79. Metformin: a review of its potential indications.
Wang YW; He SJ; Feng X; Cheng J; Luo YT; Tian L; Huang Q
Drug Des Devel Ther; 2017; 11():2421-2429. PubMed ID: 28860713
[TBL] [Abstract][Full Text] [Related]
80. Metformin in Differentiated Thyroid Cancer: Molecular Pathways and Its Clinical Implications.
García-Sáenz M; Lobaton-Ginsberg M; Ferreira-Hermosillo A
Biomolecules; 2022 Apr; 12(4):. PubMed ID: 35454163
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
